| The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis PH Maxwell, MS Wiesener, GW Chang, SC Clifford, EC Vaux, ... Nature 399 (6733), 271-275, 1999 | 6211 | 1999 |
| Hypoxia-inducible expression of tumor-associated carbonic anhydrases CC Wykoff, NJP Beasley, PH Watson, KJ Turner, J Pastorek, A Sibtain, ... Cancer research 60 (24), 7075-7083, 2000 | 1597 | 2000 |
| Diabetic retinopathy: a position statement by the American Diabetes Association SD Solomon, E Chew, EJ Duh, L Sobrin, JK Sun, BL VanderBeek, ... Diabetes care 40 (3), 412, 2017 | 975 | 2017 |
| HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron SJ Mandriota, KJ Turner, DR Davies, PG Murray, NV Morgan, HM Sowter, ... Cancer cell 1 (5), 459-468, 2002 | 622 | 2002 |
| Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma SK Chia, CC Wykoff, PH Watson, C Han, RD Leek, J Pastorek, KC Gatter, ... Journal of Clinical Oncology 19 (16), 3660-3668, 2001 | 531 | 2001 |
| Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth JA Engelman, CC Wykoff, S Yasuhara, KS Song, T Okamoto, MP Lisanti Journal of Biological Chemistry 272 (26), 16374-16381, 1997 | 486 | 1997 |
| Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer A Giatromanolaki, MI Koukourakis, E Sivridis, J Pastorek, CC Wykoff, ... Cancer research 61 (21), 7992-7998, 2001 | 443 | 2001 |
| Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial DS Liao, FV Grossi, D El Mehdi, MR Gerber, DM Brown, JS Heier, ... Ophthalmology 127 (2), 186-195, 2020 | 435 | 2020 |
| Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non–small-cell lung cancer DEB Swinson, JL Jones, D Richardson, C Wykoff, H Turley, J Pastorek, ... Journal of Clinical Oncology 21 (3), 473-482, 2003 | 367 | 2003 |
| Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling CC Wykoff, CW Pugh, PH Maxwell, AL Harris, PJ Ratcliffe Oncogene 19 (54), 6297-6305, 2000 | 345 | 2000 |
| Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density NJP Beasley, CC Wykoff, PH Watson, R Leek, H Turley, K Gatter, ... Cancer research 61 (13), 5262-5267, 2001 | 330 | 2001 |
| Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double … JS Heier, AM Khanani, CQ Ruiz, K Basu, PJ Ferrone, C Brittain, ... The Lancet 399 (10326), 729-740, 2022 | 311 | 2022 |
| Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results CC Wykoff, DE Croft, DM Brown, R Wang, JF Payne, L Clark, ... Ophthalmology 122 (12), 2514-2522, 2015 | 297 | 2015 |
| Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast CC Wykoff, N Beasley, PH Watson, L Campo, SK Chia, R English, ... The American journal of pathology 158 (3), 1011-1019, 2001 | 286 | 2001 |
| Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two … CC Wykoff, F Abreu, AP Adamis, K Basu, DA Eichenbaum, Z Haskova, ... The Lancet 399 (10326), 741-755, 2022 | 269 | 2022 |
| Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy MI Koukourakis, A Giatromanolaki, E Sivridis, K Simopoulos, J Pastorek, ... Clinical Cancer Research 7 (11), 3399-3403, 2001 | 259 | 2001 |
| Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial J Sahni, SS Patel, PU Dugel, AM Khanani, CD Jhaveri, CC Wykoff, ... Ophthalmology 126 (8), 1155-1170, 2019 | 231 | 2019 |
| Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes A Lingappan, CC Wykoff, TA Albini, D Miller, A Pathengay, JL Davis, ... American journal of ophthalmology 153 (1), 162-166. e1, 2012 | 221 | 2012 |
| Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes IP Stolze, YM Tian, RJ Appelhoff, H Turley, CC Wykoff, JM Gleadle, ... Journal of Biological Chemistry 279 (41), 42719-42725, 2004 | 210 | 2004 |
| Exogenous fungal endophthalmitis: microbiology and clinical outcomes CC Wykoff, HW Flynn Jr, D Miller, IU Scott, EC Alfonso Ophthalmology 115 (9), 1501-1507. e2, 2008 | 208 | 2008 |
David M Brown MD FACSDirector of Research, Retina Consultants of Houston在 houstonretina.com 的电子邮件经过验证
David M Brown MD FACSDirector of Research, Retina Consultants of Houston在 houstonretina.com 的电子邮件经过验证